Pfizer's OTC sales decline by 6% in the US

28 July 2015 - Deborah Wilkes

Archived

Sales by Pfizer's Consumer Healthcare business in the US dropped by 6% in the second quarter of 2015, despite a "strong performance" from Nexium (esomeprazole) as it entered its second year as an OTC medicine.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: